AstraZeneca completes Cellectis equity investment | 07-May-2024 | 07:00 | RNS |
Calquence combination improved PFS in 1L MCL | 02-May-2024 | 07:00 | RNS |
Total Voting Rights | 01-May-2024 | 15:00 | RNS |
Truqap recommended for EU breast cancer approval | 29-Apr-2024 | 07:05 | RNS |
Enhertu improved PFS in HER2-low and ultralow | 29-Apr-2024 | 07:00 | RNS |
1st Quarter Results | 25-Apr-2024 | 07:00 | RNS |
Result of AGM | 11-Apr-2024 | 17:30 | RNS |
AstraZeneca increases 2024 dividend by 7% | 11-Apr-2024 | 07:00 | RNS |
Enhertu approved in US for HER2+ solid tumours | 08-Apr-2024 | 07:00 | RNS |
Imfinzi improved OS & PFS in limited-stage SCLC | 05-Apr-2024 | 07:00 | RNS |
Total Voting Rights | 02-Apr-2024 | 15:00 | RNS |
Voydeya approved in US | 02-Apr-2024 | 07:05 | RNS |
FDA accepts Dato-DXd BLA for breast cancer | 02-Apr-2024 | 07:00 | RNS |
Ultomiris approved in the US for NMOSD | 25-Mar-2024 | 07:00 | RNS |
AstraZeneca to acquire Fusion | 19-Mar-2024 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 12,118.00p |
Change Today | 68.00p |
% Change | 0.56 % |
52 Week High | 12,170.00 |
52 Week Low | 9,501.00 |
Volume | 2,560,495 |
Shares Issued | 1,550.24m |
Market Cap | £187,858m |
RiskGrade | 123 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 8 |
Buy | 15 |
Neutral | 5 |
Sell | 0 |
Strong Sell | 1 |
Total | 29 |
Latest | Previous | |
---|---|---|
2nd Interim | 1st Interim | |
Ex-Div | 22-Feb-24 | 10-Aug-23 |
Paid | 25-Mar-24 | 11-Sep-23 |
Amount | 197.00¢ | 93.00¢ |
Time | Volume / Share Price |
16:27 | 189,952 @ 11,966.00p |
16:27 | 189,952 @ 11,966.00p |
16:49 | 1,018 @ 12,118.00p |
16:35 | 460,721 @ 12,118.00p |
16:35 | 100 @ 12,118.00p |
You are here: research